<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174627</url>
  </required_header>
  <id_info>
    <org_study_id>D5740C00001</org_study_id>
    <nct_id>NCT02174627</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment
      of anemia in patients with chronic kidney disease not on dialysis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in anemic
      patients with Stage 3, 4 or 5 chronic kidney disease (CKD) who are not on dialysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2014</start_date>
  <completion_date type="Actual">October 4, 2018</completion_date>
  <primary_completion_date type="Actual">October 4, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52</measure>
    <time_frame>Baseline (Day 1, Week 0) and Week 28 to Week 52.</time_frame>
    <description>Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hb Response During the First 24 Weeks of Treatment</measure>
    <time_frame>Baseline (Day 1, Week 0) up to Week 24.</time_frame>
    <description>Hb response was defined as:
Hb ≥ 11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL for participants with baseline Hb &gt; 8.0 g/dL; or
Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at 2 consecutive visits (with available data) separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell [RBC] transfusion, erythropoietin analogue, or intravenous [IV] iron) prior to Hb response. The percentage of participants with an Hb response during the first 24 weeks of treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)</measure>
    <time_frame>Baseline (Day 1, Week 0) and Week 28 to Week 52.</time_frame>
    <description>Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value during Week 28 to Week 52 was analyzed using a MAR based multiple imputation ANCOVA model with baseline Hb, baseline eGFR, CV history, geographic region and treatment group as fixed effect covariates. The adjusted LS mean estimates of change from baseline in participants with baseline hsCRP &gt;ULN to mean during Week 28 to Week 52 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52</measure>
    <time_frame>Week 28 up to Week 52.</time_frame>
    <description>Proportion of total time of interpolated Hb values ≥10 g/dL was calculated as the time the linearly interpolated curve between measurements ≥10 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52</measure>
    <time_frame>Week 28 up to Week 52.</time_frame>
    <description>Proportion of total time of interpolated Hb values within the interval of 10 to 12 g/dL was calculated as the time the linearly interpolated curve between measurements were within 10 to 12 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24</measure>
    <time_frame>Baseline (Day 1, Week 0) and Week 24</time_frame>
    <description>Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analyzed using an ANCOVA model with baseline LDL, baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy</measure>
    <time_frame>Baseline (Day1, Week 0) up to End of Study (EOS) visit (4 weeks after the treatment period) (or up to date of first rescue therapy), with treatment duration up to 4 years.</time_frame>
    <description>Time-to-first rescue therapy (IV iron, RBC transfusion or erythropoietin analogue) was calculated as (date of first rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy</measure>
    <time_frame>Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period) (or up to date of first RBC rescue therapy), with treatment duration up to 4 years.</time_frame>
    <description>Time-to-first RBC rescue therapy was calculated as (date of first RBC rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28</measure>
    <time_frame>Baseline (Day 1, Week 0) and Week 12 to Week 28.</time_frame>
    <description>SF-36 is a Quality of Life (QoL) scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Vitality sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a mixed model for repeated measures (MMRM) with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant</measure>
    <time_frame>Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period), with treatment duration up to 4 years.</time_frame>
    <description>Baseline eGFR was defined as the mean of all available central laboratory values prior to or at randomization. Rate of change in eGFR from baseline during the entire treatment period (in millilitres/minute/1.73 meters squared/years [mL/min/1.73m^2/years]) was estimated using a random effects model using all post-baseline eGFR values prior to initiation of dialysis/transplant. Baseline eGFR, baseline Hb, geographic region, CV history, treatment group and post-baseline eGFR measurement time were used as fixed effects and participant and time (years) as random effects, ie, random intercept and slope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28</measure>
    <time_frame>Baseline (Day 1, Week 0) and Week 12 to Week 28.</time_frame>
    <description>SF-36 is a QoL scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Physical Functioning sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a MMRM with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2781</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.</description>
    <arm_group_label>Roxadustat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures.

          2. Age ≥18 years at screening visit 1

          3. eGFR &lt;60 mL/min/1.73 m2, (calculated by central lab) corresponding to stage 3, 4 or
             5CKD according to the Kidney Disease Outcomes Quality Initiative (KDOQI), not
             receiving dialysis

          4. Mean of 2 most recent central laboratory Hb values during the screening period,
             obtained at least 7 days apart, must be &lt;10.0 g/dL

          5. Ferritin ≥50 ng/mL at randomization (obtained from screening visit)

          6. TSAT ≥15 % at randomization (obtained from screening visit)

          7. Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from
             screening visit)

          8. Serum vitamin B12 level ≥LLN at randomization (obtained from screening visit)

          9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper limit
             of normal (ULN) and total bilirubin (Tbili) ≤1.5 x ULN at randomization (obtained from
             screening visit)

         10. Body weight 45 to 160 kg

        Exclusion Criteria:

          1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)

          2. Previous randomization in the present study

          3. Any erythropoietin analogue treatment within 6 weeks of randomization

          4. New York Heart Association Class III or IV congestive heart failure at enrollment

          5. Myocardial infarction (MI), acute coronary syndrome, stroke, seizure or a
             thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism)
             within 12 weeks prior to randomization

          6. History of chronic liver disease (e.g., chronic infectious hepatitis, chronic auto-
             immune liver disease, cirrhosis or fibrosis of the liver)

          7. Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a
             history of pure red cell aplasia or other known causes for anemia other than CKD

          8. Known and untreated retinal vein occlusion or known and untreated proliferative
             diabetic retinopathy (risk for retinal vein thrombosis)

          9. Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV)
             of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan
             or MRI) conducted at screening or within 12 weeks prior to randomization

         10. Systolic BP ≥160 mmHg or diastolic BP ≥95 mmHg (confirmed by repeated measurement),
             within 2 weeks prior to randomization. Patients may be rescreened once BP controlled

         11. History of prostate cancer, breast cancer or any other malignancy, except the
             following: cancers determined to be cured or in remission for ≥5 years, curatively
             resected basal cell or squamous cell skin cancers, cervical cancer in situ, or
             resected colonic polyps

         12. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)

         13. Chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus
             erythematosus (SLE), ankylosing spondylitis, psoriatic arthritis or inflammatory bowel
             disease that is determined to be the principal cause of anemia

         14. Known hemosiderosis, hemochromatosis or hypercoagulable condition

         15. Any prior organ transplant or a scheduled organ transplantation date

         16. Any red blood cell transfusion (RBC) during the screening period

         17. Any current condition leading to active significant blood loss

         18. Any treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase
             inhibitor (HIF-PHI)

         19. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) or has participated in any other clinical study that included
             drug treatment within at least 1 month of the first administration of IP in this
             study. (Note: patients consented and screened, but not randomized in this study or a
             previous study are not excluded)

         20. History of alcohol or drug abuse within 2 years prior to randomization

         21. Females of childbearing potential, unless using contraception as detailed in the
             protocol or sexual abstinence

         22. Pregnant or breastfeeding females

         23. Known allergy to the investigational product or any of its ingredients

         24. Any medical condition, including active, clinically significant infection, that in the
             opinion of the investigator or Sponsor may pose a safety risk to a patient in this
             study, which may confound efficacy or safety assessment or may interfere with study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Fishbane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Houser, MD</last_name>
    <role>Study Director</role>
    <affiliation>AZ R&amp;D Gaithersburg, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Grange</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New Hampshire</state>
        <zip>03867</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1440AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autónoma de Bs. As.</city>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudadela</city>
        <zip>1702</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Plata</city>
        <zip>C1427ARO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lanus</city>
        <zip>B1824KAJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munro</city>
        <zip>1605</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramos Mejía</city>
        <zip>B1704ETD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <zip>S2000DNM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Isidro</city>
        <zip>B1642DCD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80440-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80810-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Feira de Santana</city>
        <zip>44001-584</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <zip>60115282</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiânia</city>
        <zip>74043-011</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Joinville</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Juiz de Fora</city>
        <zip>36036-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maringa</city>
        <zip>87083-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90160-093</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Bernardo do Campo</city>
        <zip>09715090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01323-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Botevgrad</city>
        <zip>2140</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gotse Delchev</city>
        <zip>2900</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samokov</city>
        <zip>2000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandanski</city>
        <zip>2800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silistra</city>
        <zip>7500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolyan</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <zip>V2C 2T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2V 3M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1P 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2H 5Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K 3V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1H 3G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whitby</city>
        <state>Ontario</state>
        <zip>L1N 5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cali</city>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chia</city>
        <zip>250008</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <zip>5001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zipaquira</city>
        <zip>250258</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Havlickuv Brod</city>
        <zip>580 22</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivancice</city>
        <zip>664 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>190 61</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slavkov u Brna</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sumperk</city>
        <zip>787 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajka</city>
        <zip>8400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Polgár</city>
        <zip>4090</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salgótarján</city>
        <zip>3100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siófok</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Velence</city>
        <zip>2481</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <zip>600006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ghaziabad NCR</city>
        <zip>201012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500072</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkatta</city>
        <zip>700027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucknow</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maharashtra</city>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mysore</city>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <zip>420012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vijayawada</city>
        <zip>520 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vijayawada</city>
        <zip>522002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vishakhapatnam</city>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ansan-si</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10444</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>139-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uijeongbu-si</city>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>George Town</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kubang Kerian</city>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taiping</city>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20219</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Culiacán</city>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44676</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minatitlán</city>
        <zip>96730</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>México</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veracruz</city>
        <zip>91900</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xalapa</city>
        <zip>91020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellavista</city>
        <zip>CALLAO 2</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ica</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>L17</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trujillo</city>
        <zip>044</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciechanów</city>
        <zip>06-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Końskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tczew</city>
        <zip>83-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cidra</city>
        <zip>00739</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio Grande</city>
        <zip>00745</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toa Baja</city>
        <zip>00949</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arad</city>
        <zip>310017</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>010731</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540000</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>109263</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>129344</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>404120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kralovsky Chlmec</city>
        <zip>077 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 34</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keelung</city>
        <zip>20401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Taipei</city>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Taipei</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>0116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10491</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>TaoYuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khmelnytsky</city>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirovograd</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <zip>43005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rivne</city>
        <zip>33027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Can Tho</city>
        <zip>900000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hochiminh</city>
        <zip>550000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hochiminh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hue</city>
        <zip>530000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5740C00001&amp;amp;attachmentIdentifier=e591fa4d-7259-4500-bf4c-783f4239fab9&amp;amp;fileName=D5740C00001_redacted_CSP_from_PRS.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5740C00001&amp;amp;attachmentIdentifier=cf047ffd-547d-4bee-b970-58c377627038&amp;amp;fileName=D5740C00001_SAP-v3_Redacted_28-Sep-2018.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>October 4, 2019</results_first_submitted>
  <results_first_submitted_qc>November 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2019</results_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal,</keyword>
  <keyword>CKD,</keyword>
  <keyword>Roxadustat,</keyword>
  <keyword>anemia,</keyword>
  <keyword>non-dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02174627/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 385 centers in 25 countries worldwide across the United States, Canada, Latin America, Asia and Europe between 26 June 2014 and 04 October 2018. Participants with chronic kidney disease who were not on dialysis were recruited in this study.</recruitment_details>
      <pre_assignment_details>Study had a screening period (up to 6 weeks), treatment period (up to 4 years) and follow-up period (4 weeks after treatment period for those who completed treatment). 2781 participants were randomized, of which 2761 were included in the analysis and 20 were excluded. Only participants included in the analysis are presented in the participant flow.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally three times a week (TIW). The initial dose was 70 milligram (mg) TIW and was titrated to achieve and maintain haemoglobin (Hb) 11±1 grams per deciliter (g/dL). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1384"/>
                <participants group_id="P2" count="1377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1384"/>
                <participants group_id="P2" count="1376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Treatment</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="801"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1300"/>
                <participants group_id="P2" count="1247"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment before randomization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant decision</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intention-To-Treat (ITT) analysis set included all participants who were randomized to investigational product (IP) irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1384"/>
            <count group_id="B2" value="1377"/>
            <count group_id="B3" value="2761"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="14.67"/>
                    <measurement group_id="B2" value="62.4" spread="14.14"/>
                    <measurement group_id="B3" value="61.7" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="820"/>
                    <measurement group_id="B2" value="774"/>
                    <measurement group_id="B3" value="1594"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="564"/>
                    <measurement group_id="B2" value="603"/>
                    <measurement group_id="B3" value="1167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="344"/>
                    <measurement group_id="B2" value="357"/>
                    <measurement group_id="B3" value="701"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1040"/>
                    <measurement group_id="B2" value="1020"/>
                    <measurement group_id="B3" value="2060"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="623"/>
                    <measurement group_id="B2" value="611"/>
                    <measurement group_id="B3" value="1234"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="544"/>
                    <measurement group_id="B2" value="538"/>
                    <measurement group_id="B3" value="1082"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52</title>
        <description>Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0) and Week 28 to Week 52.</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52</title>
          <description>Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1334"/>
                <count group_id="O2" value="1330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.033"/>
                    <measurement group_id="O2" value="0.40" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in LS mean changes; MAR-based multiple imputation ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the lower bound of the 2-sided 95% confidence interval (CI) of the difference between roxadustat and placebo exceeded 0 g/dL.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hb Response During the First 24 Weeks of Treatment</title>
        <description>Hb response was defined as:
Hb ≥ 11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL for participants with baseline Hb &gt; 8.0 g/dL; or
Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at 2 consecutive visits (with available data) separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell [RBC] transfusion, erythropoietin analogue, or intravenous [IV] iron) prior to Hb response. The percentage of participants with an Hb response during the first 24 weeks of treatment is presented.</description>
        <time_frame>Baseline (Day 1, Week 0) up to Week 24.</time_frame>
        <population>The Full Analysis Set (FAS) included all participants in the ITT analysis set who received at least 1 dose of IP and had baseline Hb and at least 1 post-dose Hb assessment. Participants from the FAS, with data available for analysis are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Response During the First 24 Weeks of Treatment</title>
          <description>Hb response was defined as:
Hb ≥ 11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL for participants with baseline Hb &gt; 8.0 g/dL; or
Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at 2 consecutive visits (with available data) separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell [RBC] transfusion, erythropoietin analogue, or intravenous [IV] iron) prior to Hb response. The percentage of participants with an Hb response during the first 24 weeks of treatment is presented.</description>
          <population>The Full Analysis Set (FAS) included all participants in the ITT analysis set who received at least 1 dose of IP and had baseline Hb and at least 1 post-dose Hb assessment. Participants from the FAS, with data available for analysis are presented.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1371"/>
                <count group_id="O2" value="1357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0"/>
                    <measurement group_id="O2" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the percentage of responders for roxadustat versus placebo was analysed using a Cochran-Mantel-Haenszel test adjusting for baseline Hb, baseline eGFR, geographic region and CV history.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Relative Risk</param_type>
            <param_value>9.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.63</ci_lower_limit>
            <ci_upper_limit>10.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)</title>
        <description>Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value during Week 28 to Week 52 was analyzed using a MAR based multiple imputation ANCOVA model with baseline Hb, baseline eGFR, CV history, geographic region and treatment group as fixed effect covariates. The adjusted LS mean estimates of change from baseline in participants with baseline hsCRP &gt;ULN to mean during Week 28 to Week 52 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0) and Week 28 to Week 52.</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Only participants who consented to the use of donated biomarker samples and had baseline hsCRP &gt;ULN were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)</title>
          <description>Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value during Week 28 to Week 52 was analyzed using a MAR based multiple imputation ANCOVA model with baseline Hb, baseline eGFR, CV history, geographic region and treatment group as fixed effect covariates. The adjusted LS mean estimates of change from baseline in participants with baseline hsCRP &gt;ULN to mean during Week 28 to Week 52 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Only participants who consented to the use of donated biomarker samples and had baseline hsCRP &gt;ULN were included in the analysis.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.087"/>
                    <measurement group_id="O2" value="0.62" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in LS mean changes; MAR-based multiple imputation ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the lower bound of the 2-sided 95% CI of the difference between roxadustat and placebo exceeded 0 g/dL.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.112</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52</title>
        <description>Proportion of total time of interpolated Hb values ≥10 g/dL was calculated as the time the linearly interpolated curve between measurements ≥10 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.</description>
        <time_frame>Week 28 up to Week 52.</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52</title>
          <description>Proportion of total time of interpolated Hb values ≥10 g/dL was calculated as the time the linearly interpolated curve between measurements ≥10 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
          <units>proportion of total time</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1220"/>
                <count group_id="O2" value="1145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.011"/>
                    <measurement group_id="O2" value="0.33" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in LS mean changes; ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the lower bound of the 2-sided 95% CI of the difference between roxadustat and placebo exceeded 0.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52</title>
        <description>Proportion of total time of interpolated Hb values within the interval of 10 to 12 g/dL was calculated as the time the linearly interpolated curve between measurements were within 10 to 12 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.</description>
        <time_frame>Week 28 up to Week 52.</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52</title>
          <description>Proportion of total time of interpolated Hb values within the interval of 10 to 12 g/dL was calculated as the time the linearly interpolated curve between measurements were within 10 to 12 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
          <units>proportion of total time</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1220"/>
                <count group_id="O2" value="1145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.010"/>
                    <measurement group_id="O2" value="0.28" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in LS mean changes; ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the lower bound of the 2-sided 95% CI of the difference between roxadustat and placebo exceeded 0.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24</title>
        <description>Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analyzed using an ANCOVA model with baseline LDL, baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0) and Week 24</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24</title>
          <description>Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analyzed using an ANCOVA model with baseline LDL, baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>millimole per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1147"/>
                <count group_id="O2" value="1133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.028"/>
                    <measurement group_id="O2" value="-0.02" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in LS mean changes; ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the lower bound of the 2-sided 95% CI of the difference between roxadustat and placebo exceeded 0.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.033</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy</title>
        <description>Time-to-first rescue therapy (IV iron, RBC transfusion or erythropoietin analogue) was calculated as (date of first rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
        <time_frame>Baseline (Day1, Week 0) up to End of Study (EOS) visit (4 weeks after the treatment period) (or up to date of first rescue therapy), with treatment duration up to 4 years.</time_frame>
        <population>The on-treatment plus 28 days (OT+28) analysis set included all participants who received at least 1 dose of randomized IP, except for those excluded from analysis. Participants were censored 28 days after last intake of IP.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy</title>
          <description>Time-to-first rescue therapy (IV iron, RBC transfusion or erythropoietin analogue) was calculated as (date of first rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
          <population>The on-treatment plus 28 days (OT+28) analysis set included all participants who received at least 1 dose of randomized IP, except for those excluded from analysis. Participants were censored 28 days after last intake of IP.</population>
          <units>Events per 100 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1384"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.90"/>
                    <measurement group_id="O2" value="39.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatments were compared using a Cox proportional hazards model, with baseline Hb and baseline eGFR as continuous variables used as covariates, and treatment group, CV history and geographic region as fixed effects. The Efron method was used for ties and p-values were calculated using the Wald test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the upper limit of the 2-sided 95% CI for the HR was ≤1.0.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy</title>
        <description>Time-to-first RBC rescue therapy was calculated as (date of first RBC rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
        <time_frame>Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period) (or up to date of first RBC rescue therapy), with treatment duration up to 4 years.</time_frame>
        <population>The OT+28 analysis set included all participants who received at least 1 dose of randomized IP, except for those excluded from analysis. Participants were censored 28 days after last intake of IP.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy</title>
          <description>Time-to-first RBC rescue therapy was calculated as (date of first RBC rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
          <population>The OT+28 analysis set included all participants who received at least 1 dose of randomized IP, except for those excluded from analysis. Participants were censored 28 days after last intake of IP.</population>
          <units>Events per 100 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1384"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98"/>
                    <measurement group_id="O2" value="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatments were compared using a Cox proportional hazards model, with baseline Hb and baseline eGFR as continuous variables used as covariates, and treatment group, CV history and geographic region as fixed effects. The Efron method was used for ties and p-values were calculated using the Wald test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the upper limit of the 2-sided 95% CI for the HR was ≤1.0.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28</title>
        <description>SF-36 is a Quality of Life (QoL) scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Vitality sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a mixed model for repeated measures (MMRM) with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0) and Week 12 to Week 28.</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28</title>
          <description>SF-36 is a Quality of Life (QoL) scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Vitality sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a mixed model for repeated measures (MMRM) with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.231"/>
                    <measurement group_id="O2" value="1.15" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in LS mean changes; MMRM analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the lower bound of the 2-sided 95% CI of the difference between roxadustat and placebo exceeded 0.</non_inferiority_desc>
            <p_value>0.120</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.283</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant</title>
        <description>Baseline eGFR was defined as the mean of all available central laboratory values prior to or at randomization. Rate of change in eGFR from baseline during the entire treatment period (in millilitres/minute/1.73 meters squared/years [mL/min/1.73m^2/years]) was estimated using a random effects model using all post-baseline eGFR values prior to initiation of dialysis/transplant. Baseline eGFR, baseline Hb, geographic region, CV history, treatment group and post-baseline eGFR measurement time were used as fixed effects and participant and time (years) as random effects, ie, random intercept and slope.</description>
        <time_frame>Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period), with treatment duration up to 4 years.</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant</title>
          <description>Baseline eGFR was defined as the mean of all available central laboratory values prior to or at randomization. Rate of change in eGFR from baseline during the entire treatment period (in millilitres/minute/1.73 meters squared/years [mL/min/1.73m^2/years]) was estimated using a random effects model using all post-baseline eGFR values prior to initiation of dialysis/transplant. Baseline eGFR, baseline Hb, geographic region, CV history, treatment group and post-baseline eGFR measurement time were used as fixed effects and participant and time (years) as random effects, ie, random intercept and slope.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>eGFR rate (mL/min/1.73m^2/years)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1326"/>
                <count group_id="O2" value="1314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.70"/>
                    <measurement group_id="O2" value="-3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in rate of change in eGFR; random effects analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>Nominal p-value (as prior sequential outcome measure p-value did not meet &lt; 0.05.</p_value_desc>
            <method>Random Effects Analysis</method>
            <param_type>Rate of Change Difference</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.254</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28</title>
        <description>SF-36 is a QoL scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Physical Functioning sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a MMRM with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0) and Week 12 to Week 28.</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28</title>
          <description>SF-36 is a QoL scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Physical Functioning sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a MMRM with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.222"/>
                    <measurement group_id="O2" value="-0.39" spread="0.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between groups (roxadustat minus placebo) in LS mean changes; MMRM analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of roxadustat compared with placebo would be declared if the lower bound of the 2-sided 95% CI of the difference between roxadustat and placebo exceeded 0.</non_inferiority_desc>
            <p_value>0.051</p_value>
            <p_value_desc>Nominal p-value (as prior sequential outcome measure p-value did not meet &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.269</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of randomization up to EOS visit (4 weeks after the treatment period), with treatment duration up to 4 years.</time_frame>
      <desc>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. All-Cause Mortality represents all deaths due to any cause.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally TIW. The initial dose was 70 mg TIW and was titrated to achieve and maintain Hb 11±1 g/dL. Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally TIW. Dosing instructions were matched to instructions provided for roxadustat (ie, initial dose matched to 70 mg TIW). Treatment started on Day 1 and treatment duration was variable for individual participants (estimated up to 4 years). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks until Week 52, every 8 weeks thereafter using a dose adjustment algorithm; all dose adjustments were based on Hb values.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="284" subjects_at_risk="1384"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="795" subjects_at_risk="1384"/>
                <counts group_id="E2" subjects_affected="749" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Evans syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="1384"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1384"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1384"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="1384"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1384"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="1384"/>
                <counts group_id="E2" events="42" subjects_affected="31" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chronic left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1384"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Heart valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Metabolic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1384"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vestibular ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic gastropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dieulafoy's vascular malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Duodenitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Femoral hernia incarcerated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="1384"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="1384"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peritoneal cloudy effluent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Uraemic gastropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="1384"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="1384"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hernia pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Implant site extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Implant site necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="1384"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oedema due to renal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="1384"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pacemaker generated arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhagic hepatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Device allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal transplant failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cardiac valve abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="1384"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1384"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Emphysematous cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Emphysematous pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Endotoxic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Fungal peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="1384"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatitis B reactivation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Infective aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Intestinal tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="1384"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="149" subjects_affected="113" subjects_at_risk="1384"/>
                <counts group_id="E2" events="107" subjects_affected="88" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="1384"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="49" subjects_at_risk="1384"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="1384"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Streptococcal endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Taeniasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="36" subjects_at_risk="1384"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="1384"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular access site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chemical peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dialysis disequilibrium syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dialysis related complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Periorbital haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peritoneal dialysis complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Shunt malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Spleen contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Stoma obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular access malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular access site thrombosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Wound haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Coagulation factor decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Adult failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Calciphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="1384"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Food aversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="1384"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperinsulinaemic hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="41" subjects_at_risk="1384"/>
                <counts group_id="E2" events="35" subjects_affected="25" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="1384"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Epiglottic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Neoplasm of appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour of the lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebellar stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1384"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Coma uraemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic hyperosmolar coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidotic hyperglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Facial spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1384"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Neurodegenerative disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Post stroke seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vertigo CNS origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vestibular migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular cognitive impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="1384"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="61" subjects_at_risk="1384"/>
                <counts group_id="E2" events="79" subjects_affected="60" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1384"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="211" subjects_affected="199" subjects_at_risk="1384"/>
                <counts group_id="E2" events="211" subjects_affected="201" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Nephritic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oedematous kidney</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal papillary necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal pelvis fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urinary fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urinary tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Prostatic fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Prostatic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1384"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1384"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bronchial fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1384"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="1384"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pleural thickening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1384"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Respiratory alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Necrobiosis lipoidica diabeticorum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Distributive shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="1384"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="33" subjects_at_risk="1384"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="1384"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1384"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Iliac artery perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Paget-Schroetter syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Post thrombotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Subclavian artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1384"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Visceral congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1384"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="839" subjects_at_risk="1384"/>
                <counts group_id="E2" subjects_affected="757" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="126" subjects_affected="91" subjects_at_risk="1384"/>
                <counts group_id="E2" events="101" subjects_affected="88" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="190" subjects_affected="138" subjects_at_risk="1384"/>
                <counts group_id="E2" events="156" subjects_affected="117" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="171" subjects_affected="124" subjects_at_risk="1384"/>
                <counts group_id="E2" events="127" subjects_affected="103" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="90" subjects_affected="75" subjects_at_risk="1384"/>
                <counts group_id="E2" events="85" subjects_affected="67" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="192" subjects_affected="144" subjects_at_risk="1384"/>
                <counts group_id="E2" events="135" subjects_affected="106" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="80" subjects_affected="72" subjects_at_risk="1384"/>
                <counts group_id="E2" events="76" subjects_affected="64" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="137" subjects_affected="95" subjects_at_risk="1384"/>
                <counts group_id="E2" events="100" subjects_affected="75" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="205" subjects_affected="152" subjects_at_risk="1384"/>
                <counts group_id="E2" events="135" subjects_affected="94" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="159" subjects_affected="101" subjects_at_risk="1384"/>
                <counts group_id="E2" events="152" subjects_affected="106" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="105" subjects_affected="86" subjects_at_risk="1384"/>
                <counts group_id="E2" events="86" subjects_affected="75" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="85" subjects_affected="73" subjects_at_risk="1384"/>
                <counts group_id="E2" events="61" subjects_affected="53" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="87" subjects_affected="70" subjects_at_risk="1384"/>
                <counts group_id="E2" events="69" subjects_affected="57" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="91" subjects_affected="74" subjects_at_risk="1384"/>
                <counts group_id="E2" events="113" subjects_affected="86" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="122" subjects_affected="93" subjects_at_risk="1384"/>
                <counts group_id="E2" events="96" subjects_affected="82" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="93" subjects_affected="93" subjects_at_risk="1384"/>
                <counts group_id="E2" events="88" subjects_affected="87" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="123" subjects_affected="105" subjects_at_risk="1384"/>
                <counts group_id="E2" events="91" subjects_affected="69" subjects_at_risk="1377"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="85" subjects_affected="70" subjects_at_risk="1384"/>
                <counts group_id="E2" events="80" subjects_affected="64" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="84" subjects_affected="68" subjects_at_risk="1384"/>
                <counts group_id="E2" events="89" subjects_affected="80" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="190" subjects_affected="148" subjects_at_risk="1384"/>
                <counts group_id="E2" events="151" subjects_affected="117" subjects_at_risk="1377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>20 participants were excluded from the analysis due to Good Clinical Practice violations or system technical issues (9 in roxadustat group and 11 in placebo group). Higher IP discontinuation was observed in placebo group versus in roxadustat group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Clinical Lead</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 302 885 1180</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

